Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDG-PET/CT to predict early response to anti-PD-1/PD-L1 therapy in advanced NSCLC
jRCTs031180036Completed
- Sponsor
- Nihon Medi-Physics Co., Ltd.
- Start
- Mar 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab and pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Nihon Medi-Physics Co., Ltd. Primary endpoints: Change in SUVmax, MTV, and TLG and association with efficacy of anti-PD-1/PD-L1 antibodies and Timing of FDG-PET/CT assessment at 4 and 9 weeks. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031180036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180036.